Article

About 3-5% of all patients with multiple sclerosis experience the onset of their
disease under the age of 16. A significant proportion of paediatric multiple
sclerosis patients develop significant cognitive disturbances and persistent
physical disability. The high relapse rate and the morbidity in the paediatric
multiple sclerosis population has triggered the use of disease-modifying
therapies that have been shown to reduce relapse rate, disease progression and
cognitive decline in adult patients with multiple sclerosis. Hard evidence for
the right treatment and its appropriate timing is scarce in paediatric multiple
sclerosis. Nevertheless, expertise in this field has grown thanks to recent
open-label trials and experience generated in specialized centres. In spring
2009, a first meeting was held in Rotterdam with clinicians from 11 European
countries (one from Canada) that are all active in the management of paediatric
multiple sclerosis. One of the aims was to generate a common view on the
management of paediatric multiple sclerosis patients. The result of this meeting
is presented here to help standardize treatment and to support clinicians with
less experience in this field.

Langue : ANGLAIS

Tiré à part : OUI